← Oncology Approval Tracker

FDA DECISION ·

Vyxeos

daunorubicin and cytarabine liposome · Jazz Pharmaceuticals

FDA approvalNew or expanded indicationAcute myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Expansion to patients as young as 1 year with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

LAMPGEN ANALYSIS

Why it matters

The action extends a fixed-ratio liposomal regimen into defined pediatric secondary AML populations.

What research teams should watch

Verify age, AML subtype and treatment history, and align pediatric safety and dosing documentation.

PRIMARY RECORDS

Sources